Access to medicines is shaped not only by regulatory frameworks, pricing structures, and supply systems, but also by how medicines are understood and accepted by the people who use them. In South Africa, generic medicines have been part of the healthcare system for decades, while biosimilars are becoming increasingly relevant in the treatment of complex and chronic conditions. Both categories are subject to rigorous regulatory standards. However, levels of public understanding and confidence can influence how widely they are used in practice.
Generic medicines are developed to be therapeutically equivalent to originator medicines once patent protection expires. This means they contain the same active ingredient, are administered in the same way, and are required to demonstrate comparable bioavailability. Regulatory authorities, including SAHPRA, require evidence of bioequivalence to ensure that generics perform in the same manner as their reference products. These standards are aligned with international regulatory practices, including those of the World Health Organization and other established agencies.
Biosimilars, while often discussed alongside generics, differ in important ways. They are developed from biological sources and are designed to be highly similar to an already approved reference biologic. Due to the complexity of biological products, biosimilars undergo extensive comparative evaluation, including analytical, preclinical, and clinical studies, to demonstrate similarity in terms of quality, safety, and efficacy. Regulatory pathways for biosimilars are therefore distinct, reflecting the nature of the products involved.
Despite these regulatory safeguards, perceptions around generics and biosimilars can vary. Some patients may associate lower cost with lower quality, while others may be unfamiliar with how these medicines are evaluated and approved. In certain cases, changes in medication appearance, such as differences in packaging or tablet colour, can contribute to uncertainty, even when the active ingredient remains the same.
Healthcare providers play an important role in supporting patient understanding. Clear communication from prescribers and pharmacists can help explain why a generic or biosimilar has been recommended, how it compares to the original product, and what patients can expect in terms of treatment outcomes. Consistent messaging across the healthcare system contributes to a more informed patient base.
At the same time, patients themselves are active participants in the medicine use process. Decisions to accept substitution, ask questions, and adhere to prescribed treatment all contribute to the effectiveness of healthcare interventions. When patients are informed about the equivalence of generics and the regulatory standards governing biosimilars, they are better positioned to engage with their treatment plans.
From a system perspective, the uptake of generics and biosimilars is associated with broader sustainability considerations. These medicines can support more efficient use of healthcare resources by enabling wider access within existing budgets. In public sector programmes, this contributes to the ability to treat larger patient populations. In the private sector, it can influence out-of-pocket costs and benefit design within medical schemes.
The relationship between patient confidence and medicine utilisation has been observed in multiple settings. Studies have shown that where patients receive clear information about generic substitution, acceptance rates tend to increase, supporting continuity of care. Similarly, structured education around biosimilars has been associated with improved uptake in countries where these medicines have been introduced into treatment protocols.
In South Africa, regulatory and professional bodies have developed guidelines to support the safe use of generics and biosimilars, including provisions for substitution and pharmacovigilance. Pharmacovigilance systems, which monitor the safety of medicines after they are in use, provide an additional layer of oversight, ensuring that any adverse events are identified and managed appropriately.
Public-facing education remains an important component of this framework. Accessible information on how medicines are approved, how equivalence is established, and how safety is monitored can contribute to a more transparent healthcare environment. Community-based education initiatives, pharmacy engagement, and patient support programmes all play a role in strengthening this understanding.
It is also relevant to recognise that confidence in medicines is influenced by broader factors, including trust in healthcare providers, consistency of supply, and overall experience within the healthcare system. Efforts to improve medicine availability, streamline communication, and maintain quality standards all contribute to a more stable environment in which patients can engage with their treatment.
As the South African healthcare system continues to evolve, generics and biosimilars are expected to remain central to discussions around access and sustainability. Their role is defined not only by regulatory approval and clinical evidence, but also by how they are integrated into everyday practice.
Building confidence is therefore a shared process. It involves clear regulatory standards, consistent clinical guidance, and informed patient participation. Through this combination, generics and biosimilars can continue to support access to safe and effective treatment, while contributing to the long-term sustainability of the healthcare system.